Frailty in liver cirrhosis ‒ insights into prevalence, determinants, and clinical impact from a tertiary center experience

Authors

  • Omkolsoum Alhaddad Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt
  • Maha Elsabaawy Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt https://orcid.org/0000-0002-3110-1547
  • Asmaa Abedelhai Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt
  • Gamal Badra Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt
  • Marwa Elfayoumy Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt

DOI:

https://doi.org/10.15584/ejcem.2025.4.4

Keywords:

cirrhosis, frailty, prevalence

Abstract

Introduction and aim. Frailty has emerged as a critical determinant of poor outcomes in patients with liver cirrhosis. This study aims to determine the prevalence and predictors of frailty in patients with liver cirrhosis and assess its clinical impact on disease severity.

Material and methods. This cross-sectional study included 460 patients with liver cirrhosis were classified into frail Clinical Frailty Scale (CFS) >4 and non-frail (CFS≤4) groups.

Results. The prevalence of frailty among the studied patients was 45.7%. Frail patients were significantly older (60.61±9.06 years), without gender predilection (43.7%, 47.9%). Patients with frailty exhibited significantly worse liver function; higher bilirubin (1.30 (0.90–2.0) vs 0.90 (0.66–1.30) mg/dL, p<0.001) and low albumin (3.9 (3.50–4.10) vs 3.2 (2.60–3.70) g/dL, p<0.001). Multivariate analysis identified age (OR=1.055, 95%CI: 1.023–1.088, p<0.001), body mass index (OR=9.803, 95%CI: 5.067–18.963, p<0.001), and high nutritional risk (OR=20.186, 95%CI: 8.456–48.191, p<0.001) as independent predictors of frailty.

Conclusion. Frailty is a significant concern in patients with liver cirrhosis, particularly those with advanced age, diabetes, and severe hepatic dysfunction. Optimizing outcomes for this patient population requires a multi-faceted approach that considers liver disease management, routine frailty assessment, and interventions to enhance physical resilience and address co-morbidities.

Downloads

Download data is not yet available.

References

Martin FC, O'Halloran AM. Tools for Assessing Frailty in Older People: General Concepts. Adv Exp Med Biol. 2020;1216:9-19. doi: 10.1007/978-3-030-33330-0_2

Tandon P, Zanetto A, Piano S, Heimbach JK, Dasarathy S. Liver transplantation in the patient with physical frailty. J Hepatol. 2023;78(6):1105-1117. doi:10.1016/j.jhep.2023.03.025

Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75(1):S147-S162. doi:10.1016/j.jhep.2021.01.025

Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases [published correction appears in Hepatology. 2021;74(6):3563. doi:10.1002/hep.32224]. Hepatology. 2021;74(3):1611-1644. doi: 10.1002/hep.32049

Harris SJ, Stine JG. Frailty in liver transplantation: exploring prescribing exercise as medicine to improve patient outcomes. Liver Int. 2024;44(9):2251-2262. doi: 10.1111/liv.15986

Niwa T, Saeki C, Saito M, et al. Impact of frailty and prevalent fractures on the long-term prognosis of patients with cirrhosis: a retrospective study. Sci Rep. 2025;15(1):186. doi: 10.1038/s41598-024-83984-2

Padhi BK, Gandhi AP, Sandeep M, et al. Prevalence of frailty and its impact on mortality and hospitalization in patients with cirrhosis: a systematic review and meta-analysis. J Clin Exp Hepatol. 2024;14(4):101373. doi: 10.1016/j.jceh.2024.101373

Deng Y, Sato N. Global frailty screening tools: review and application of frailty screening tools from 2001 to 2023. Intractable Rare Dis Res. 2024;13(1):1-11. doi: 10.5582/irdr.2023.01113

Wiedermann CJ, Barbieri V, Ausserhofer D, Engl A, Piccoliori G, Mahlknecht A. Sex bias in frailty screening: a cross-sectional analysis of PRISMA-7 and the Clinical Frailty Scale in primary care. Diagnostics. 2025;15(7):915. doi: 10.3390/diagnostics15070915

Kotak PS, Kumar J, Kumar S, Varma A, Acharya S. Navigating cirrhosis: a comprehensive review of liver scoring systems for diagnosis and prognosis. Cureus. 2024;16(3):e57162. doi: 10.7759/cureus.57162

Geladari E, Alexopoulos T, Vasilieva L, et al. Evaluation of five screening tools in detecting physical frailty in cirrhosis and their prognostic role. J Clin Med. 2024;13(17):5169. doi: 10.3390/jcm13175169

Kremer WM, Nagel M, Reuter M, et al. Validation of the Clinical Frailty Scale for the prediction of mortality in patients with liver cirrhosis. Clin Transl Gastroenterol. 2020;11(7):e00211. doi: 10.14309/ctg.0000000000000211

Schleicher EM, Kremer WM, Kalampoka V, et al. Frailty as tested by the Clinical Frailty Scale is a risk factor for hepatorenal syndrome in patients with liver cirrhosis. Clin Transl Gastroenterol. 2022;13(7):e00512. doi: 10.14309/ctg.0000000000000512

Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7(2):126-135. doi: 10.1002/jcsm.12039

Wu Y, Zhu Y, Feng Y, et al. Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition in liver cirrhosis. Br J Nutr. 2020;124(12):1293-1302. doi: 10.1017/S0007114520002546

Lai JC, Covinsky KE, McCulloch CE, Feng S. The Liver Frailty Index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113(2):235-242. doi: 10.1038/ajg.2017.443

Singh S, Taneja S, Tandon P, et al. A comparison of different frailty scores and impact of frailty on outcome in patients with cirrhosis. J Clin Exp Hepatol. 2022;12(2):398-408. doi: 10.1016/j.jceh.2021.07.003

Elsheikh M, El Sabagh A, Mohamed IB, Bhongade M, Hassan MM, Jalal PK. Frailty in end-stage liver disease: understanding pathophysiology, tools for assessment, and strategies for management. World J Gastroenterol. 2023;29(46):6028-6048. doi: 10.3748/wjg.v29.i46.6028

Puri P, Dhiman RK, Taneja S, et al. Nutrition in chronic liver disease: consensus statement of the Indian National Association for Study of the Liver. J Clin Exp Hepatol. 2021;11(1):97-143. doi: 10.1016/j.jceh.2020.09.003

Loschi TM, Baccan MDTA, Della Guardia B, Martins PN, Boteon APCS, Boteon YL. Exercise training as an intervention for frailty in cirrhotic patients on the liver transplant waiting list: a systematic review. World J Hepatol. 2023;15(10):1153-1163. doi: 10.4254/wjh.v15.i10.1153

Duarte-Rojo A, Ruiz-Margáin A, Montaño-Loza AJ, Macías-Rodríguez RU, Ferrando A, Kim WR. Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl. 2018;24(1):122-139. doi: 10.1002/lt.24958

Quint EE, Ferreira M, van Munster BC, et al. Prehabilitation in adult solid organ transplant candidates. Curr Transplant Rep. 2023;10(2):70-82. doi: 10.1007/s40472-023-00395-4

Jayanama K, Theou O, Godin J, Mayo A, Cahill L, Rockwood K. Relationship of body mass index with frailty and all-cause mortality among middle-aged and older adults. BMC Med. 2022;20(1):404. doi: 10.1186/s12916-022-02596-7

Wei S, Nguyen TT, Zhang Y, Ryu D, Gariani K. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol (Lausanne). 2023;14:1185221. doi: 10.3389/fendo.2023.1185221

Downloads

Published

2025-06-05

How to Cite

Alhaddad, O., Elsabaawy, M., Abedelhai, A., Badra, G., & Elfayoumy, M. (2025). Frailty in liver cirrhosis ‒ insights into prevalence, determinants, and clinical impact from a tertiary center experience. European Journal of Clinical and Experimental Medicine. https://doi.org/10.15584/ejcem.2025.4.4

Issue

ONLINE FIRST

Section

ORIGINAL PAPERS

License

Copyright (c) 2025 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.